We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the most undervalued pharma stocks.
TheFly reported on May 11 that Piper Sandler reduced its price target on AMPH from $25 to $21 while maintaining a Neutral stance on the stock following the company’s quarterly results. The firm noted that AMPH has several complex generic products and branded opportunities in its pipeline, but there is limited clarity on when these programs will begin to generate meaningful results. This lack of visibility into the timing of potential pipeline catalysts contributed to the revised outlook.
Earlier on May 7, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its financial results for the first quarter ended March 31, 2026. The company posted net revenues of $171.2 million for the period. Reported GAAP net income came in at $6.4 million, translating to earnings of $0.14 per share. On an adjusted non-GAAP basis, net income was $19.5 million, or $0.42 per share.
The results reflect performance across its portfolio of technically complex generic and proprietary injectable, inhalation, and intranasal products. The figures provide a snapshot of profitability under both standard accounting measures and adjusted metrics that exclude certain items. These quarterly outcomes highlight the company’s financial position and operational results for the period, offering investors a view of revenue generation and earnings performance during the first quarter of fiscal 2026.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops and markets generic and proprietary injectable, inhalation, and intranasal products. It focuses on complex, hard-to-make medications used in hospitals and clinical settings.
TheFly reported on May 11 that Piper Sandler reduced its price target on AMPH from $25 to $21 while maintaining a Neutral stance on the stock following the company’s quarterly results. The firm noted that AMPH has several complex generic products and branded opportunities in its pipeline, but there is limited clarity on when these programs will begin to generate meaningful results. This lack of visibility into the timing of potential pipeline catalysts contributed to the revised outlook.
Earlier on May 7, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its financial results for the first quarter ended March 31, 2026. The company posted net revenues of $171.2 million for the period. Reported GAAP net income came in at $6.4 million, translating to earnings of $0.14 per share. On an adjusted non-GAAP basis, net income was $19.5 million, or $0.42 per share.
The results reflect performance across its portfolio of technically complex generic and proprietary injectable, inhalation, and intranasal products. The figures provide a snapshot of profitability under both standard accounting measures and adjusted metrics that exclude certain items. These quarterly outcomes highlight the company’s financial position and operational results for the period, offering investors a view of revenue generation and earnings performance during the first quarter of fiscal 2026.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops and markets generic and proprietary injectable, inhalation, and intranasal products. It focuses on complex, hard-to-make medications used in hospitals and clinical settings.
16 hours ago
